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Intratibial injection of an anti-doxorubicin monoclonal
antibody prevents drug-induced myelotoxicity in mice
D Morelli1, S Menard', S Cazzaniga1, Ml Colnaghi1 and A Balsari2
'Division of Experimental Oncology E, Istituto Nazionale Tumori and2lnstitute of Pathology, University of Milan, Via Venezian 1, 20133 Milan, Italy
Summary With few exceptions, the major limit to high-dose chemotherapeutic treatments is the severity and duration of drug-induced
myelosuppression. We have recently developed a monoclonal antibody, MAD11, which reacts with the potent anti-tumour antibiotic
doxorubicin and other anthracyclines. To protect directly pluripotent stem cells and cells of the haematopoietic microenvironment in the bone
marrow against doxorubicin cytotoxicity, the monoclonal antibody MAD11 was injected into the tibial bone of mice before chemotherapeutic
treatment. All mice pretreated intratibially with MAD11 and injected with 14 mg kg-' bodyweight of doxorubicin survived, whereas 41% of mice
treated with doxorubicin alone died. At a higher dose of doxorubicin (18 mg kg-1), early mortality (first 6 days) was similar in the groups, but
no deaths were observed thereafter in the intratibially MAD 11-treated group, whereas most of the mice treated with doxorubicin alone died.
Data obtained in mice injected with P388 leukaemia cells showed that the intratibial injection of MAD11 did not compromise the anti-tumoral
activity of doxorubicin. Moreover, the administration of the anti-doxorubicin monoclonal antibody before chemotherapeutic treatment
effectively reduced apoptosis induced by doxorubicin in the bone marrow cells. These data suggest the usefulness of monoclonal antibodies
against chemotherapeutic drugs in the local protection of bone marrow without influencing the anti-tumour properties of the drug.
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Bone marrow toxicity ofdrugs has until now been the main draw-
back of antineoplastic chemotherapy. The deterioration of the
haematopoietic stem cell pool often leads to modification of
planned protocols, although the anti-tumour efficacy is clearly
dose dependent (Guigon et al, 1994).
Numerous strategies have been devised, based mainly on marrow
transplantation and stimulation of surviving cells, to reduce the
severity and duration of drug-induced pancytopenia without
compromising the anti-tumour efficacy of the treatment. However,
while autologous bone marrow transplantation has allowed the use
of more intensive myeloablative therapies, infection-related
morbidity and mortality can be present during the period of
haematopoietic reconstitution (Chesson et al, 1989; Gulati et al,
1991). Autografting of peripheral blood stem cells or progenitors
harvested by leukapheresis before chemotherapy can speed
haematopoietic recovery (Henon et al, 1992; Roberts et al, 1992;
Henon, 1993). Moreover,expansion ofsurviving progenitorpopula-
tions and, thereby, an increased output of mature cells has recently
been obtained using haematopoietic growth factors, either alone or
in combination with bone marrow or peripheral blood stem cell
(PBSC) reinfusion (Metcalf, 1990; Lieschke et al, 1992). Most of
these haematopoietic growth factors are produced in the bone by the
haematopoietic microenvironment comprised of an admixture of
several adherent cell types, including fibroblasts, reticular adventi-
tial cells and macrophages (Dexter, 1989; Eaves et al, 1991). One
could envisage that the protection from drug-induced damage of
both stem cells and haematopoietic microenvironment is an alterna-
tive approach to reduce the post-treatment periods ofneutropenia.
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The anthracycline, doxorubicin, is widely used in the treatment
of solid human tumours, but its usefulness is limited by acute bone
marrow toxicity, gastrointestinal mucositis and chronic cumulative
dose cardiac toxicity (Weiss, 1992; Chabner et al, 1993). Given the
relatively short plasma half-life of doxorubicin, a strategy that
protects bone marrow during and shortly after the administration
of a bolus injection of doxorubicin would be expected to reduce
the extent of damage to pluripotent stem cells and to cells of the
haematopoietic microenvironment.
We have derived a monoclonal antibody, named MAD11, which
reacts with doxorubicin and other anthracyclines and reduces
doxorubicin-induced body weight loss and alopecia in mice
(Balsari et al, 1991, 1994; Sardini et al, 1992; Morelli et al, 1996).
In this study, we evaluated the ability of the monoclonal antibody,
MAD11, administered directly in mouse tibial bone marrow to
protect against doxorubicin-induced myelotoxicity.
MATERIAL AND METHODS
Mice
Six- to eight-week-old female BALB/c and C57BL/6 x DBA2
(hereafter called BD2-Fl) mice were obtained from Charles River
(Calco, Italy). All mice were treated in accordance with
Institutional guidelines. For intratibial injection and before sacri-
fice, mice were anaesthetized with 0.2 ml per 20 g body weight of
10 mg ml ketamine and 0.05% xylazine.
Cell lines
Leukaemia cell line, P388, was obtained from the American Type
Culture Collection (ATCC, Rockville, MD, USA) and maintained
in BD2-F1 mice by weekly i.p. transplantation.
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Figure 1 Effect of intratibial injection of MAD11 on survival of BALB/c mice
treated with 14 mg kg-' body weight of doxorubicin. Doxorubicin alone (O),
doxorubicin plus MAD11 i.v. (-) and doxorubicin plus MAD11 intratibially (0).
The treatment schedule was as described in Materials and methods
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Figure 2 Effect of intratibial injection of MAD11 on survival of BD2-F1 mice
injected i.p. with P388 leukaemia cells and treated with 16 mg kg-' body
weight of doxorubicin. Untreated mice (0), mice treated with doxorubicin
alone (X) and mice treated with doxorubicin plus MAD11 intratibially (0). The
treatment schedule was as described in Materials and methods
Reagents
Doxorubicin hydrochloride (adriamycin) was supplied by
Pharmacia Carlo Erba (Milan, Italy). A fresh solution of doxoru-
bicin was prepared just before use. The anti-doxorubicin mono-
clonal antibody, MAD 11 (IgG2a), specifically recognizes epitopes
located at or near the aromatic D ring of the anthracycline mole-
cule (Balsari et al, 1990).
Intratibial injection of MADi 1
After induction of anaesthesia, a 27-gauge needle was inserted, as
described (Berlin et al, 1993), in the proximal part of the tibia
tuberosity and twisted through the cortical bone. Once the cortex
was traversed, the needle was inserted into the metaphysis and
diaphysis ofthe bone, and 100 jil ofMAD 11 was injected.
Quantitation of MAD11 recovery in tibia
Purified MAD11 was radiolabelled by lactoperoxidase-catalysed
iodination to a specific activity of 11.2 ,uCi ug-'. Three anaes-
thetized BALB/c mice were each injected intratibially with 100 pl
of labelled MADI1 (2x106 c.p.m.), sacrificed 30 min later and
tibias were tested for radioactivity in a gamma-counter.
Effect of intratibially injected MAD11 on survival of
doxorubicin-treated mice
In Experiment I, 54 BALB/c mice were randomly divided into
three groups and treated with 300 ,ug ofMAD11 in 100 glofsaline
intratibially, the same dose ofantibody i.v. or with 100 pl ofsaline
intratibially 10 min before i.p. injection with 14 mg kg-' body
weight ofdoxorubicin.
In Experiment II,40 BALB/c mice were randomly divided into
two groups and either treated or not with 300 gg ofMAD11 in 100
gl of saline intratibially 10 min before injection of 18 mg kg-'
body weight ofdoxorubicin.
The influence ofMAD 11 on the anti-tumour activity ofdoxoru-
bicin was evaluated in three groups of BD2-F1 mice (eight mice
per group) transplanted i.p. with 106 P388 leukaemia cells. One
day later, one group was injected with 1000 ,ug of MAD11 intrati-
bially followed by i.p. injection with 16 mg kg-' body weight of
doxorubicin; a second group was treated with doxorubicin only
and the third group was not treated. Statistical significance was
assessed using X2 analysis.
Effect of MAD11 on doxorubicin-induced bone marrow
apoptosis
BALB/c mice were injected in the right tibia with 50 jig of
MAD1I or with saline, and 10 min later with 16 mg kg-' body
weight of doxorubicin. After 8 h, bone marrow cells were aspi-
rated from the paired tibias with cold RPMI medium, washed
twice and 105cells were plated on glass slides. Cells were air dried
and fixed with 4% paraformaldehyde and washed twice with phos-
phate-buffered saline (PBS). After permeabilization for 2 min on
ice (4°C) in a solution containing 0.1% Triton X-100 and 0.1%
sodium citrate, cells were incubated with 45 U per 150 pl per slide
of terminal deoxynucleotidyl transferase (TdT) (Boehringer-
Mannheim) plus 30 gM fluoresceinated dUTP (Boehringer-
Mannheim) in lx TdT buffer for 1 h at 37°C. Cells were rinsed in
PBS and visualized by epifluorescence using standard fluorescein
excitation and emission filters. Statistical significance was
assessed using Student's t-test.
RESULTS
Injection studies using trypan blue established that up to 100 ,ul of
reagent could be delivered into the medullary canal of the murine
tibia without gross cortical fracture. Biodistribution studies in
which radiolabelled MAD 1 (2x106 c.p.m.) was injected into the
medullary canal of the right tibia of three mice showed that, after
30 min, 30.001±3.381 c.p.m. of radioactivity was present in the
injected bone. At the same time, the radioactivity detected in the
contralateral legs was 340±148 c.p.m.
To determine whether the injection of MAD11 in tibial bone
marrow might protect against doxorubicin-induced myelotoxicity-
related death, 54 BALB/c mice were randomly divided into three
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Figure 3 Effect of intratibial injection of MAD11 on doxorubicin-induced
apoptosis. Bone marrow from (a) an untreated mouse, (b) a doxorubicin-
treated mouse, (c and d) two doxorubicin-treated mice: (O) MAD11- treated
right tibia (3) and contralateral tibia. Values are the mean±s.d. of the
percentage of apoptotic cells present in five fields. The treatment schedule
was as described in Materials and methods
groups and treated with 300 ,ug of MAD 11 in the right tibia, the
same dose ofthe monoclonal antibody given i.v., or with 100gl of
saline intratibially, and after 10 min, all mice were treated i.p. with
14 mg kg-' body weight of doxorubicin. During the next 40 days,
none of the mice in the intratibially MAD11-treated group died
(0/19), whereas 33.3% (6/18) ofmice treated i.v. and 41.2% (7/17)
of mice treated only with doxorubicin died (Figure 1). The protec-
tion against mortality in intratibially MADI1-treated mice was
statistically significant (P<0.002 vs doxorubicin only-treated mice;
P<0.008 vs i.v. MADI I plus doxorubicin-treated mice).
In a second experiment, 40 mice received a higher dose of
doxorubicin (18 mg kg-' weight); 18 ofthese mice were pretreated
intratibially with MAD 1. In the first 6 days, no differences in the
percentage of deaths were observed in the two groups [27.8%
(5/18) in intratibially MAD11-treated mice and 27.3% (6/22) in
mice treated with doxorubicin only]. In the surviving animals, no
deaths were observed thereafter in intratibially MADI1-treated
mice (0/13), whereas 50% (8/16) ofmice treated with doxorubicin
alone died (P<0.003).
To assess the effect of MAD11 that escaped into the blood-
stream on the chemotherapeutic effect of doxorubicin, hybrid
BD2-FI mice were injected with P388 leukaemia cells and treated
with doxorubicin alone or with doxorubicin plus 1000 ,ug of
MAD11 in the right tibia. Death of all BD2-FI mice, which
tolerate high doses of doxorubicin, was caused by progression of
the tumour; as shown in Figure 2, the survival curve of leukaemic
BD2-F1 mice treated with doxorubicin and MAD11 was superim-
posable on that of mice receiving doxorubicin alone.
Doxorubicin has been reported to induce cytotoxic effects with
the characteristics of apoptosis in cells from different tissues
(Barry et al, 1990; Anilkumar et al, 1992), i.e. nuclear and cyto-
plasmic condensation and preservation of the organelles in the
early stages. Fluorescence microscopy of bone marrow cells from
mice injected i.p. with 16 mg kg-' body weight of doxorubicin
revealed evidence ofcell death in bone marrow obtained 2, 4, 8, 16
and 32 h after treatment. The morphological features were similar
in all samples studied but considerable differences existed in the
frequency of dead cells with a maximum at 8 h (unpublished
results). To test whether intratibial injection of MADI1 protects
bone marrow cells from doxorubicin-induced apoptosis, mice
Figure 4 Photomicrograph of bone marrow cells from MAD11-treated right
tibia (A) and contralateral tibia (B) of a mouse treated with 16 mg kg-' body
weight of doxorubicin. Apoptotic nuclei were visualized by labelling the
fragmented DNA with fluoresceinated dUTP via the terminal transferase
(TdT) reaction
were injected in the right tibia with 50 jig of MAD11 and then
treated i.p. with 16 mg kg-' body weight ofdoxorubicin. As shown
in Figure 3 and 4, the percentage ofapoptotic cells in the MAD 11-
treated tibia was significantly (P<0.0001, Figure 3c; P<0.001,
Figure 3d) lower than in the contralateral tibia.
DISCUSSION
In this study, we show that an anti-doxorubicin monoclonal anti-
body directly injected in the tibial bone of mice can protect the
bone marrow against the toxic effects ofhigh-dose doxorubicin.
Several growth factors and inhibitors that prevent chemo-
therapy-induced myelosuppression are now available. These
reagents have a reversible stimulatory or inhibitory action on the
cycling of early stem cells and precursors or late progenitors. In
the past 10 years, much attention has focused on the rapid recovery
induced by colony-stimulating factors (CSFs). However, the long-
term effects should not be overlooked, and both overt and latent
marrow failure represents a hazard (Tubiana et al, 1993).
Moreover, some recent experimental data suggest that repeated
growth factor stimulation may contribute to exhaustion ofthe stem
cell pool (Homung et al, 1992; Moore, 1992). Indeed, a network of
finely tuned regulatory factors is required to control normal
haemopoiesis or regeneration following an insult, and drugs can
also affect haemopoietic stem cells indirectly by their toxicity to
bone marrow stromal cells and damage to the stem cell microenvi-
ronment (Schofield, 1986). If the damage to haemopoietic stem
cells is not ultimately lethal, depletion is followed by recovery at a
rate that depends on the proliferation rate ofcolony-forming units
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(CFUs) and on the rate of differentiation into committed cell
compartments (Vassort et al, 1971), both under the regulation of
the stem cell microenvironment. Thus, new strategies to minimize
damage to all bone marrow components should be explored.
Two different doses of doxorubicin were used in evaluating the
protective effect ofMADi 1. With doxorubicin at 14 mg kg-' body
weight, no death was observed in intratibially MADI1-treated
mice during the entire experiment compared with a 41% death rate
in mice treated with doxorubicin only. With 18 mg kg-' doxoru-
bicin, a similar percentage ofmortality was observed in the intrat-
ibially MADI1-treated groups and in control groups for the first 6
days; this early mortality can be ascribed to non-haematological
reasons, since high doses of doxorubicin are also toxic for organs
other than bone marrow, consistent with a previous study
(Grzegorzewski et al, 1994) showing that bone marrow transplan-
tation did not protect from acute doxorubicin toxicity. After the
nadir ofdoxorubicin-induced myelodepression on day 7 (Mazue et
al, 1995), statistically significant protection against mortality in
intratibially MADI1-treated mice was observed.
The administration of the anti-doxorubicin monoclonal anti-
body before chemotherapeutic treatment was effective in reducing
doxorubicin-induced apoptosis, raising the possibility that the
increase in survival and the capacity to repopulate lethally irradi-
ated mice is related to an inhibition of doxorubicin-induced apop-
tosis in bone marrow cells.
Future therapeutic strategies to prevent myelosuppression might
involve the combination of inhibitory molecules able to maintain
haematopoietic stem cells in a quiescent state temporarily, thus
protecting them from intensive chemotherapy, together with
cytokines, such as granulocyte colony-stimulating factor (G-CSF),
which are capable of accelerating haematopoietic recovery. Other
new strategies, such as antisense oligonucleotides, anti-receptor
reagents and multidrug resistance gene therapy, also appear
promising for clinical use.
Our data show that monoclonal antibodies directed against
chemotherapeutic drugs can be used for the local protection ofthe
bone marrow in mice receiving high-dose chemotherapy without
interfering with the anti-tumour properties of the drug. Since chil-
dren's long bones contain bone marrow and the cortical bone can
be easily injected, the intratibial administration of this antibody
could provide an alternative approach to protect bone marrow cells
locally in young patients with solid tumours.
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